Curi RMB Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.18M | Buy |
52,418
+148
| +0.3% | +$8.63K | 0.06% | 271 |
|
|
2025
Q4 | $2.82M | Buy |
52,270
+30,997
| +146% | +$1.49M | 0.05% | 288 |
|
|
2025
Q3 | $959K | Sell |
21,273
-188
| -0.9% | -$8.78K | 0.02% | 426 |
|
|
2025
Q2 | $993K | Buy |
21,461
+16,592
| +341% | +$814K | 0.02% | 416 |
|
|
2025
Q1 | $297K | Sell |
4,869
-15,666
| -76% | -$913K | 0.01% | 436 |
|
|
2024
Q4 | $1.16M | Sell |
20,535
-358
| -2% | -$20K | 0.03% | 319 |
|
|
2024
Q3 | $1.08M | Sell |
20,893
-52
| -0.2% | -$2.44K | 0.02% | 333 |
|
|
2024
Q2 | $870K | Sell |
20,945
-478
| -2% | -$21.4K | 0.02% | 348 |
|
|
2024
Q1 | $1.16M | Buy |
21,423
+3,895
| +22% | +$198K | 0.03% | 330 |
|
|
2023
Q4 | $899K | Buy |
17,528
+1,051
| +6% | +$55.2K | 0.03% | 305 |
|
|
2023
Q3 | $956K | Buy |
16,477
+144
| +0.9% | +$8.82K | 0.03% | 281 |
|
|
2023
Q2 | $1.04M | Buy |
16,333
+3,100
| +23% | +$208K | 0.03% | 281 |
|
|
2023
Q1 | $917K | Sell |
13,233
-37
| -0.3% | -$2.61K | 0.03% | 290 |
|
|
2022
Q4 | $955K | Sell |
13,270
-780
| -6% | -$58.8K | 0.03% | 293 |
|
|
2022
Q3 | $999K | Buy |
14,050
+69
| +0.5% | +$5K | 0.04% | 282 |
|
|
2022
Q2 | $1.08M | Buy |
13,981
+179
| +1% | +$13.6K | 0.04% | 271 |
|
|
2022
Q1 | $1.01M | Buy |
13,802
+50
| +0.4% | +$3.36K | 0.03% | 254 |
|
|
2021
Q4 | $857K | Sell |
13,752
-49
| -0.4% | -$2.87K | 0.03% | 298 |
|
|
2021
Q3 | $817K | Sell |
13,801
-945
| -6% | -$62.2K | 0.03% | 293 |
|
|
2021
Q2 | $985K | Buy |
14,746
+1,802
| +14% | +$118K | 0.03% | 281 |
|
|
2021
Q1 | $817K | Sell |
12,944
-52,439
| -80% | -$3.26M | 0.03% | 288 |
|
|
2020
Q4 | $4.06M | Sell |
65,383
-17,980
| -22% | -$1.11M | 0.15% | 142 |
|
|
2020
Q3 | $5.03M | Buy |
83,363
+24,503
| +42% | +$1.47M | 0.22% | 110 |
|
|
2020
Q2 | $3.46M | Buy |
58,860
+878
| +2% | +$52.5K | 0.15% | 140 |
|
|
2020
Q1 | $3.23M | Sell |
57,982
-24,160
| -29% | -$1.48M | 0.15% | 147 |
|
|
2019
Q4 | $5.27M | Buy |
82,142
+4,772
| +6% | +$273K | 0.15% | 160 |
|
|
2019
Q3 | $3.92M | Buy |
77,370
+2,970
| +4% | +$140K | 0.1% | 197 |
|
|
2019
Q2 | $3.37M | Buy |
74,400
+5,861
| +9% | +$273K | 0.09% | 233 |
|
|
2019
Q1 | $3.27M | Buy |
68,539
+31,417
| +85% | +$1.56M | 0.08% | 250 |
|
|
2018
Q4 | $1.93M | Sell |
37,122
-398
| -1% | -$21.4K | 0.05% | 349 |
|
|
2018
Q3 | $2.33M | Buy |
37,520
+92
| +0.2% | +$5.46K | 0.06% | 348 |
|
|
2018
Q2 | $2.07M | Sell |
37,428
-2,474
| -6% | -$134K | 0.05% | 377 |
|
|
2018
Q1 | $2.52M | Sell |
39,902
-6,056
| -13% | -$390K | 0.06% | 347 |
|
|
2017
Q4 | $2.82M | Buy |
45,958
+37,330
| +433% | +$2.33M | 0.07% | 328 |
|
|
2017
Q3 | $550K | Buy |
8,628
+1,303
| +18% | +$76.1K | 0.01% | 510 |
|
|
2017
Q2 | $408K | Sell |
7,325
-878
| -11% | -$47.8K | 0.01% | 559 |
|
|
2017
Q1 | $446K | Sell |
8,203
-179,445
| -96% | -$9.84M | 0.02% | 384 |
|
|
2016
Q4 | $11M | Buy |
187,648
+12,800
| +7% | +$700K | 0.59% | 61 |
|
|
2016
Q3 | $9.43M | Buy |
174,848
+47,295
| +37% | +$3.04M | 0.51% | 64 |
|
|
2016
Q2 | $9.38M | Sell |
127,553
-5,251
| -4% | -$371K | 0.49% | 62 |
|
|
2016
Q1 | $8.48M | Sell |
132,804
-6,254
| -4% | -$394K | 0.55% | 59 |
|
|
2015
Q4 | $9.57M | Sell |
139,058
-11,852
| -8% | -$783K | 0.44% | 50 |
|
|
2015
Q3 | $8.93M | Sell |
150,910
-4,376
| -3% | -$278K | 0.59% | 49 |
|
|
2015
Q2 | $10.3M | Sell |
155,286
-2,920
| -2% | -$192K | 0.67% | 45 |
|
|
2015
Q1 | $10.2M | Sell |
158,206
-3,318
| -2% | -$208K | 0.61% | 47 |
|
|
2014
Q4 | $9.54M | Sell |
161,524
-5,903
| -4% | -$333K | 0.58% | 49 |
|
|
2014
Q3 | $8.57M | Sell |
167,427
-4,606
| -3% | -$230K | 0.52% | 54 |
|
|
2014
Q2 | $8.35M | Buy |
+172,033
| New | +$8.48M | 0.53% | 57 |
|
Other funds holding BMY
VCM
VPM
Curi RMB Capital's BMY Position: Q1 2026 in Review
Curi RMB Capital increased its Bristol-Myers Squibb (BMY) stake by 0.28% in Q1 2026, buying an estimated $8.63K and bringing the position to 52,418 shares worth $3.18M. The position accounts for 0.06% of the portfolio, ranked #271.
Curi RMB Capital first reported a position in BMY in Q2 2014 and has held it in 48 quarters since. The position peaked at $11M in Q4 2016. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Curi RMB Capital held 52,418 shares of Bristol-Myers Squibb worth $3.18M as of Q1 2026.
- Curi RMB Capital bought 148 Bristol-Myers Squibb shares in Q1 2026, an estimated $8.63K.
- Bristol-Myers Squibb made up 0.06% of Curi RMB Capital's portfolio in Q1 2026, its #271 holding.
- Curi RMB Capital first reported a position in Bristol-Myers Squibb in Q2 2014 and has held it in 48 quarters since.
- Curi RMB Capital's Bristol-Myers Squibb position peaked at $11M in Q4 2016.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Curi RMB Capital's 13F filing for Q1 2026, filed 15 May 2026.